Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Developed international equities (MSCI EAFE) have been underperforming relative to global equities (MSCI ACWI). However, within EAFE, SMID-caps tell a different story and are a great source of investment ideas within the EAFE region. In today’s report we use a bottom-up approach to highlight actionable charts, sorted by market cap (all buys at current levels).

Developed international equities (MSCI EAFE) have been underperforming relative to global equities (MSCI ACWI). However, within EAFE, SMID-caps tell a different story and are a great source of investment ideas within the EAFE region. In today’s report we use a bottom-up approach to highlight actionable charts, sorted by market cap (all buys at current levels).

Pharma/ Biotechnology Investments Specialist, Vasuda Capital Management

Dr. Bhavneesh Sharma, MD, MBA

Pharma/ Biotechnology Investments Specialist

Vasuda Capital Management

Thematic (Sector/Industry)

Summary: We discuss <a href="https://www.smartkarma.com/entities/1427" target="_blank" data-smartkarma-citation="entities:1427">Atyr Pharma Inc (LIFE US)</a>, <a href="https://www.smartkarma.com/entities/21433" target="_blank" data-smartkarma-citation="entities:21433">DBV Technologies SA (DBV FP)</a>, <a href="https://www.smartkarma.com/entities/3285" target="_blank" data-smartkarma-citation="entities:3285">Advaxis Inc (ADXS US)</a>, <a href="https://www.smartkarma.com/entities/14350" target="_blank" data-smartkarma-citation="entities:14350">Global Blood Therapeutics Inc (GBT US)</a>, <a href="https://www.smartkarma.com/entities/9268" target="_blank" data-smartkarma-citation="entities:9268">Versartis Inc (VSAR US)</a>, Ascendis Pharma (ASND US), and Windtree Therapeutics (WINT US).<a href="https://www.smartkarma.com/entities/1427" target="_blank" data-smartkarma-citation="entities:1427:1">Atyr Pharma Inc (LIFE US)</a>, one of our watch-list companies, received FDA Fast track designation for Resolaris in the treatment of facioscapulohumeral muscle dystrophy (FSHD).  Earlier this month, the company announced successful phase 1b/2 trial results in adult FSHD. The…

Summary: We discuss Atyr Pharma Inc (LIFE US), DBV Technologies SA (DBV FP), Advaxis Inc (ADXS US), Global Blood Therapeutics Inc (GBT US), Versartis Inc (VSAR US), Ascendis Pharma (ASND US), and Windtree Therapeutics (WINT US).Atyr Pharma Inc (LIFE US), one of our watch-list companies, received FDA Fast track designation for Resolaris in the treatment of facioscapulohumeral muscle dystrophy (FSHD).  Earlier this month, the company announced successful phase 1b/2 trial results in adult FSHD. The…

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: October 24 (Monday)

France

Sartorius Stedim Biotech develops and manufactures laboratory technologies and equipment for the pharma and food industries, as well as for public research institutes and laboratories.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sartorius Stedim Biotech (DIM FP)

Focus on Outperforming EAFE SMID-Caps

Developed international equities (MSCI EAFE) have been underperforming relative to global equities (MSCI ACWI). However, within EAFE, SMID-caps...

Vermilion Research

Recap of Key Events in the U.S. Biotechnology and Pharmaceutical Sector: October 24 (Monday)

Summary: We discuss Atyr Pharma Inc (LIFE US), DBV Technologies SA (DBV FP), Advaxis Inc (ADXS US), Global Blood Therapeutics Inc (GBT US),...

Dr. Bhavneesh Sharma, MD, MBA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)